Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pharmaceutical Tourism

Bruce N. Cronstein, MD  |  Issue: November 2009  |  November 1, 2009

Most Americans are willing to subsidize the price of life-saving drugs for patients in poor countries (e.g., AIDS drugs for Africa), but I doubt that many Americans would be so sanguine about underwriting the cost of weight-loss drugs for obese Europeans or antidepressants for the Japanese. Nonetheless, American citizens do subsidize the drug development process by paying disproportionately high prices for drugs. And the subsidy for drug development flows not just to American companies but to European and Asian pharmaceutical companies as well.

Portrait of Hippocrates holding his Apophthegms.
Portrait of Hippocrates holding his Apophthegms.

Rebalancing the Drug Scales

The American consumers’ (and taxpayers’, too, through the National Institutes of Health) subsidy of the world’s drug development costs clearly contributes to the disparity in spending on healthcare in the United States and is an obvious target for reform. Nonetheless, the high cost of drugs in this country should be corrected not by reform of the healthcare system but by appropriate trade agreements. It is hard to imagine that the industrialized countries will be happy to see the end of the subsidy that Americans provide for their people, but the U.S. economy no longer has the ability to subsidize the world’s consumption of pharmaceuticals.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

If the U.S. government were to take up this imbalance and impose a solution that benefitted the American consumer, it should be revenue neutral for the pharmaceutical industry. It would be naive to assume that the pharmaceutical industry would voluntarily lower its prices for American consumers in response to a rebalancing of the cost burden for drugs in the United States. The pharmaceutical industry has rightly been reviled for its pricing and marketing practices in the United States, and is not known for its generosity to the American consumer either. So a change in the way that drugs are priced and purchased in the United States should be the quo for the quid provided by federal trade negotiations.

Getting a great price on my mother’s medications was only one of the many pleasures we all shared during our trip to Greece. Indeed, visiting the sites where so much of our culture began deeply impressed my entire family. As a physician, I enjoy knowing that our profession has roots in Greece and that we still take the oath of Hippocrates that originated in this country in the fourth century B.C. Nonetheless, it seems to be a particularly human failing to desire to improve even those things that seem complete already. Indeed, as my mother noted on visiting the Acropolis in Athens, that “they could do so much with this place if they only fixed it up a bit.” Unfortunately, I think that the people of Greece will have the same reaction to my mother’s suggestion as they will to my modest proposal for cutting the cost of medical care in the United States.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 | Single Page
Share: 

Filed under:Legislation & Advocacy Tagged with:DrugsHealthcare ReformTravel

Related Articles

    The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

    June 15, 2017

    Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

    Bending, Not Breaking

    August 16, 2019

    “And of course, I am not telling you to do it. That would be illegal.” As a general rule, I try not to instruct my patients to break the law. My business model depends on repeat customers, so placing a patient at risk of getting arrested—even if that risk is remote—doesn’t seem like a good…

    The Cost of Free Pharmaceutical Services

    October 18, 2019

    The cards sat, untouched, in a corner of my desk. In the 1800s, it was common for American saloons to provide patrons with a free meal. Of course, the meal came with a catch: The meals were predictably salt laden and designed to encourage patrons to drink more beer. Hence was born the expression, “There…

    Major Drugmakers Push Back in U.S. Price Debate

    January 15, 2016

    SAN FRANCISCO (Reuters)—With a backlash brewing over the price of medicines in the U.S., drugmakers are pushing back with a new message: Most people don’t pay retail. Top executives from Eli Lilly and Co, Merck & Co and Biogen Inc. said in interviews with Reuters this week that the media focus on retail, or “list…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences